Reata Pharmaceuticals Receives Complete Response Letter From The FDA for Bardoxolone for the Treatment of Patients with Chronic Kidney Disease Caused by Alport Syndrome

PLANO, Texas--(BUSINESS WIRE) February 25, 2022 -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the“Company,” or“we”), today announced that the U.S. Food and Drug Administration (“FDA”) has...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news